<DOC>
	<DOCNO>NCT02264080</DOCNO>
	<brief_summary>Study ass pharmacokinetics safety WAL2014 capsule administer orally multiple dose healthy adult male volunteer double blind manner .</brief_summary>
	<brief_title>Pharmacokinetics Safety WAL2014 ( Talsaclidine ) Administered Orally Healthy Adult Male Volunteers</brief_title>
	<detailed_description />
	<criteria>Subjects study healthy male adult volunteer meet inclusion criterion list fall exclusion criterion . 1 . Age : 2030 year old 2 . Body weight : 5080 kg 3 . Obesity index : within +/20 % standard body weight [ standard body weight = ( height 100 ) x 0.9 ] 4 . Those received screening examination list Table 1 within one month prior start clinical study judge eligible investigator . Results simple test gastric acidity use basis judgment . 5 . Those belong volunteer member ' association office Clinical Pharmacology Center , Ohsaki Clinic 1 . Those history allergic reaction hypersensitivity drug 2 . Those received kind drug ( ) within one week prior administration investigational product . 3 . Those ingested alcoholic drink within two day administration investigational product 4 . Those admitted hospital , undergone surgery donate blood within 3 month administration investigational product 5 . Those participated phase I clinical study drug contain new active ingredient similar study within 4 month administration investigational product 6 . Those participated Phase I single dose study investigational product 7 . Those history liver renal disease 8 . Those judge ineligible clinical study investigator</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>30 Years</maximum_age>
	<verification_date>October 2014</verification_date>
</DOC>